Management of salivary gland tumors

Guy Andry, Marc Hamoir, Laura D. Locati, Lisa Licitra, Johannes A. Langendijk

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Surgery after proper imaging (MRI or CT scan) is the main stay of treatment for salivary gland tumors. Although excision margins should be ≥5 mm for malignant tumors in cases of parotid gland carcinoma, the facial nerve should be preserved whenever it is not infiltrated. Adjuvant external radiation is indicated for malignant tumors with high-risk features such as close (or invaded) margins, perineural speed, lymphatic and/or vascular invasion, lymph-node involvement and high-grade histology. A Phase II trial testing adjuvant concomitant cisplatin plus radiation therapy versus adjuvant radiation therapy alone after surgery is currently under investigation for high-risk salivary gland cancer. For inoperable cancers, photons combined with proton boost seem to be a valuable option. Even if protons or carbon ions are promising, access to the latter is limited for usual treatment. For recurrent and/or metastatic cancer, polychemotherapy (cisplatin based) gives a 25% response rate in adenoid cystic carcinoma and should be used when the disease is overtly in progression. Targeted therapies with anti-EGF receptor molecules, antiangiogenic agents and tyrosine kinase inhibitors are ongoing, but more trials are needed to establish their efficacy, as is the use of bortezomib followed by doxorubicin. The products of fusion oncogenes, which have a pathogenic role in some adenoid cystic carcinoma and mucoepidermoid carcinomas, are of interest as potential therapeutic targets.

Original languageEnglish
Pages (from-to)1161-1168
Number of pages8
JournalExpert Review of Anticancer Therapy
Volume12
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Glandular and Epithelial Neoplasms
Adenoid Cystic Carcinoma
Cisplatin
Protons
Neoplasms
Oncogene Fusion
Radiotherapy
Salivary Gland Neoplasms
Mucoepidermoid Carcinoma
Angiogenesis Inhibitors
Oncogene Proteins
Parotid Gland
Facial Nerve
Therapeutics
Combination Drug Therapy
Photons
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Doxorubicin
Blood Vessels

Keywords

  • adenocarcinoma
  • adenoid cystic
  • chemotherapy
  • mucoepidermoid
  • pleomorphic adenoma
  • radiation therapy
  • salivary gland tumors
  • surgery
  • targeted molecular therapy

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Management of salivary gland tumors. / Andry, Guy; Hamoir, Marc; Locati, Laura D.; Licitra, Lisa; Langendijk, Johannes A.

In: Expert Review of Anticancer Therapy, Vol. 12, No. 9, 09.2012, p. 1161-1168.

Research output: Contribution to journalArticle

Andry, Guy ; Hamoir, Marc ; Locati, Laura D. ; Licitra, Lisa ; Langendijk, Johannes A. / Management of salivary gland tumors. In: Expert Review of Anticancer Therapy. 2012 ; Vol. 12, No. 9. pp. 1161-1168.
@article{660d13c960784d7e9e4f9a7a2da79e7d,
title = "Management of salivary gland tumors",
abstract = "Surgery after proper imaging (MRI or CT scan) is the main stay of treatment for salivary gland tumors. Although excision margins should be ≥5 mm for malignant tumors in cases of parotid gland carcinoma, the facial nerve should be preserved whenever it is not infiltrated. Adjuvant external radiation is indicated for malignant tumors with high-risk features such as close (or invaded) margins, perineural speed, lymphatic and/or vascular invasion, lymph-node involvement and high-grade histology. A Phase II trial testing adjuvant concomitant cisplatin plus radiation therapy versus adjuvant radiation therapy alone after surgery is currently under investigation for high-risk salivary gland cancer. For inoperable cancers, photons combined with proton boost seem to be a valuable option. Even if protons or carbon ions are promising, access to the latter is limited for usual treatment. For recurrent and/or metastatic cancer, polychemotherapy (cisplatin based) gives a 25{\%} response rate in adenoid cystic carcinoma and should be used when the disease is overtly in progression. Targeted therapies with anti-EGF receptor molecules, antiangiogenic agents and tyrosine kinase inhibitors are ongoing, but more trials are needed to establish their efficacy, as is the use of bortezomib followed by doxorubicin. The products of fusion oncogenes, which have a pathogenic role in some adenoid cystic carcinoma and mucoepidermoid carcinomas, are of interest as potential therapeutic targets.",
keywords = "adenocarcinoma, adenoid cystic, chemotherapy, mucoepidermoid, pleomorphic adenoma, radiation therapy, salivary gland tumors, surgery, targeted molecular therapy",
author = "Guy Andry and Marc Hamoir and Locati, {Laura D.} and Lisa Licitra and Langendijk, {Johannes A.}",
year = "2012",
month = "9",
doi = "10.1586/era.12.92",
language = "English",
volume = "12",
pages = "1161--1168",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "9",

}

TY - JOUR

T1 - Management of salivary gland tumors

AU - Andry, Guy

AU - Hamoir, Marc

AU - Locati, Laura D.

AU - Licitra, Lisa

AU - Langendijk, Johannes A.

PY - 2012/9

Y1 - 2012/9

N2 - Surgery after proper imaging (MRI or CT scan) is the main stay of treatment for salivary gland tumors. Although excision margins should be ≥5 mm for malignant tumors in cases of parotid gland carcinoma, the facial nerve should be preserved whenever it is not infiltrated. Adjuvant external radiation is indicated for malignant tumors with high-risk features such as close (or invaded) margins, perineural speed, lymphatic and/or vascular invasion, lymph-node involvement and high-grade histology. A Phase II trial testing adjuvant concomitant cisplatin plus radiation therapy versus adjuvant radiation therapy alone after surgery is currently under investigation for high-risk salivary gland cancer. For inoperable cancers, photons combined with proton boost seem to be a valuable option. Even if protons or carbon ions are promising, access to the latter is limited for usual treatment. For recurrent and/or metastatic cancer, polychemotherapy (cisplatin based) gives a 25% response rate in adenoid cystic carcinoma and should be used when the disease is overtly in progression. Targeted therapies with anti-EGF receptor molecules, antiangiogenic agents and tyrosine kinase inhibitors are ongoing, but more trials are needed to establish their efficacy, as is the use of bortezomib followed by doxorubicin. The products of fusion oncogenes, which have a pathogenic role in some adenoid cystic carcinoma and mucoepidermoid carcinomas, are of interest as potential therapeutic targets.

AB - Surgery after proper imaging (MRI or CT scan) is the main stay of treatment for salivary gland tumors. Although excision margins should be ≥5 mm for malignant tumors in cases of parotid gland carcinoma, the facial nerve should be preserved whenever it is not infiltrated. Adjuvant external radiation is indicated for malignant tumors with high-risk features such as close (or invaded) margins, perineural speed, lymphatic and/or vascular invasion, lymph-node involvement and high-grade histology. A Phase II trial testing adjuvant concomitant cisplatin plus radiation therapy versus adjuvant radiation therapy alone after surgery is currently under investigation for high-risk salivary gland cancer. For inoperable cancers, photons combined with proton boost seem to be a valuable option. Even if protons or carbon ions are promising, access to the latter is limited for usual treatment. For recurrent and/or metastatic cancer, polychemotherapy (cisplatin based) gives a 25% response rate in adenoid cystic carcinoma and should be used when the disease is overtly in progression. Targeted therapies with anti-EGF receptor molecules, antiangiogenic agents and tyrosine kinase inhibitors are ongoing, but more trials are needed to establish their efficacy, as is the use of bortezomib followed by doxorubicin. The products of fusion oncogenes, which have a pathogenic role in some adenoid cystic carcinoma and mucoepidermoid carcinomas, are of interest as potential therapeutic targets.

KW - adenocarcinoma

KW - adenoid cystic

KW - chemotherapy

KW - mucoepidermoid

KW - pleomorphic adenoma

KW - radiation therapy

KW - salivary gland tumors

KW - surgery

KW - targeted molecular therapy

UR - http://www.scopus.com/inward/record.url?scp=84867929227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867929227&partnerID=8YFLogxK

U2 - 10.1586/era.12.92

DO - 10.1586/era.12.92

M3 - Article

C2 - 23098116

AN - SCOPUS:84867929227

VL - 12

SP - 1161

EP - 1168

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 9

ER -